The effect of SARS-CoV-2 variants on the plasma oxylipins and PUFAs of COVID-19 patients.
COVID-19
Inflammation
Lipid mediator
Mass spectrometry
Variants
Viral infection
Journal
Prostaglandins & other lipid mediators
ISSN: 1098-8823
Titre abrégé: Prostaglandins Other Lipid Mediat
Pays: United States
ID NLM: 9808648
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
31
03
2023
revised:
16
08
2023
accepted:
22
08
2023
medline:
13
11
2023
pubmed:
27
8
2023
entrez:
26
8
2023
Statut:
ppublish
Résumé
Oxylipins are important signalling compounds that are significantly involved in the regulation of the immune system and the resolution of inflammation. Lipid metabolism is strongly activated upon SARS-CoV-2 infection, however the modulating effects of oxylipins induced by different variants remain unexplored. Here, we compare the plasma profiles of thirty-seven oxylipins and four PUFAs in subjects infected with Wild-type, Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529) variants. The results suggest that oxidative stress and inflammation resulting from COVID-19 were highly dependent on the SARS-CoV-2 variant, and that the Wild-type elicited the strongest inflammatory storm. The Alpha and Delta variants induced a comparable lipid profile alteration upon infection, which differed significantly from Omicron. The latter variant increased the levels of pro-inflammatory mediators and decreased the levels of omega-3 PUFA in infected patients. We speculate that changes in therapeutics, vaccination, and prior infections may have a role in the alteration of the oxylipin profile besides viral mutations. The results shed new light on the evolution of the inflammatory response in COVID-19.
Identifiants
pubmed: 37633481
pii: S1098-8823(23)00067-9
doi: 10.1016/j.prostaglandins.2023.106770
pii:
doi:
Substances chimiques
Oxylipins
0
Fatty Acids, Unsaturated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106770Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.